NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Niagen Bioscience, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$2.50+0.01 (+0.40%)

Close on Oct 19, 2026

Market cap: $206.26M
P/E (TTM): 13.9
Dividend yield: –

Niagen Bioscience, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-30	FY 2016 2016-12-31	FY 2015 2016-01-02	FY 2014 2015-01-03	FY 2013 2013-12-28	FY 2012 2012-12-29	FY 2011 2011-12-31	FY 2010 2011-01-01
Revenue	129	100	84	72	67	59	46	32	21	22	18	15	10	12	8.11	7.57
Cost of Revenue	46	38	33	29	26	24	21	16	11	11	10	9.99	7.03	9.34	5.64	4.62
Gross Profit	83	62	51	43	41	35	26	16	10	10	7.53	5.33	3.13	2.28	2.47	2.94
Research & Development	6.33	6.02	4.96	4.83	3.83	3.42	4.42	5.48	4.01	2.52	0.89	0.51	0.13	0.14	0.10	–
Selling, General & Admin	63	48	51	57	65	52	53	44	22	11	8.71	10.00	7.34	14	10	4.96
Selling & Marketing	36	29	26	28	28	21	18	17	4.46	1.56	1.51	2.14	2.36	5.52	2.54	1.09
General & Administrative	27	18	25	28	36	31	34	27	18	9.21	7.20	7.86	4.98	8.39	7.80	3.88
Advertising Expenses	13	11	10	11	13	7.40	6.69	8.76	1.91	0.06	0.10	0.17	0.36	2.57	0.42	–
Operating Expenses	67	54	56	61	69	55	57	49	27	13	9.60	11	7.52	14	10	4.96
Operating Income	16	7.73	-5.60	-19	-27	-20	-31	-33	-16	-2.91	-2.07	-5.23	-4.39	-12	-7.86	-2.02
Interest Expense	–	–	–	–	0.06	0.07	0.85	0.08	0.15	0.33	0.57	0.16	0.03	0.03	-0.03	0.04
Interest & Investment Income	2.13	1.13	–	–	–	–	–	–	–	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Non-Operating Income	–	–	–	–	–	-0.07	-0.85	-0.14	-0.15	-0.65	-0.57	-0.16	-0.03	-0.03	-0.03	-0.03
Asset Impairment Charges	0	0	–	–	–	–	–	–	–	0	0.02	0	0	–	0.13	–
Gain (Loss) on Sale of Assets	0.00	0.02	0.01	-0.01	0	–	-0.55	0	-5.47	0	0	-0.02	-0.07	0.00	–	–
Legal Settlements	2.00	–	–	–	–	–	–	-0.75	-0.75	–	–	–	–	–	–	–
Pretax Income	18	8.86	-4.94	–	–	–	–	–	-17	-3.55	-2.63	-5.39	-4.42	–	–	–
Income Tax Expense	0.81	0.31	0	–	–	–	–	–	0	0	0.00	0	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	-33	-17	-3.55	-2.64	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	0	5.15	0.62	-0.13	–	–	–	–	–
Net Income	17	8.55	-4.94	-17	-27	-20	-32	-33	-11	-2.93	-2.77	-5.39	-4.42	-12	-7.89	-2.05
EPS (Basic)(per share)	0.22	0.11	-0.07	-0.24	-0.40	-0.33	-0.56	-0.61	-0.26	-0.08	-0.08	-0.15	-0.12	-0.39	-0.36	–
EPS (Diluted)(per share)	0.20	0.11	-0.07	-0.24	-0.40	-0.33	-0.56	-0.61	-0.26	-0.08	-0.08	-0.15	-0.12	-0.39	-0.36	-0.12
Shares Outstanding (Basic, Weighted)(shares)	79	76	75	70	67	61	57	0.06	0.04	37	36	35	33	30	23	–
Shares Outstanding (Diluted, Weighted)(shares)	85	78	75	70	67	61	57	0.06	0.04	37	36	35	33	32	25	16
EBITDA	–	–	–	–	–	–	–	-33	-16	-2.57	-1.78	-5.01	-4.14	–	–	–
Net Interest Income	–	–	0.66	0.00	-0.06	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.2%
Operating margin: 8.2%
Net margin: 12.4%
Return on equity, FY2025: 28.3%

Financial strength

Current ratio: 6.50
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 443.5%

Valuation

P/E ratio: 13.9
Price to sales: 1.60
Price to book: 2.50
Dividend yield: –